慢性淋巴细胞白血病(CLL)是一种生长缓慢的血液骨髓癌症,通常被认为是无法治愈的,是世界上最常见的成人白血病。大多数病例CLL(95%)的开始中的白血细胞称为B细胞中的一个的缓慢生长的癌症。近日,由罗氏(Roche)与艾伯维(AbbV ie)合作开发的一款肿瘤学药物venetoclax在一项血液癌症关键Ⅱ期临床(M13-982)获得成功,为该药的监管申请铺平了道路。艾伯维已计划于年底向美国(FDA)及欧盟(EMA)提交venetoclax的上市申请。分析师 Chronic lymphocytic leukemia (CLL) is a slowly growing hematological myeloid cancer that is generally considered incurable and is the most common adult leukemia in the world. White blood cells in the beginning of most cases of CLL (95%) are called slow-growing cancers of one of the B cells. Recently, venetoclax, an oncology drug developed by Roche in collaboration with AbbVie was paved the way for a regulatory application for a key Phase II clinical trial of hematologic cancer (M13-982) the way. Albemarle has plans to file a venetoclax listing with the United States (FDA) and the European Union (EMA) by the end of the year. Analyst